ZA200605632B - UV-light stable semi-solid transdermal systems that contain a light-sensitive substance and a UV-absorber - Google Patents
UV-light stable semi-solid transdermal systems that contain a light-sensitive substance and a UV-absorber Download PDFInfo
- Publication number
- ZA200605632B ZA200605632B ZA200605632A ZA200605632A ZA200605632B ZA 200605632 B ZA200605632 B ZA 200605632B ZA 200605632 A ZA200605632 A ZA 200605632A ZA 200605632 A ZA200605632 A ZA 200605632A ZA 200605632 B ZA200605632 B ZA 200605632B
- Authority
- ZA
- South Africa
- Prior art keywords
- semisolid
- absorber
- transdermal therapeutic
- therapeutic system
- acid
- Prior art date
Links
- 239000006096 absorbing agent Substances 0.000 title claims description 26
- 239000000126 substance Substances 0.000 title claims description 11
- 239000007787 solid Substances 0.000 title claims 3
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 10
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 9
- 229960005352 gestodene Drugs 0.000 claims description 9
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 6
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 150000008366 benzophenones Chemical class 0.000 claims description 5
- -1 dioctyl butamido Chemical group 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 238000005192 partition Methods 0.000 claims description 4
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229960004400 levonorgestrel Drugs 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000000583 progesterone congener Substances 0.000 claims description 3
- OIQXFRANQVWXJF-ACCUITESSA-N (2e)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound CC1(C)C2CCC1(C)C(=O)\C2=C\C1=CC=CC=C1 OIQXFRANQVWXJF-ACCUITESSA-N 0.000 claims description 2
- PDHSAQOQVUXZGQ-JKSUJKDBSA-N (2r,3s)-2-(3,4-dihydroxyphenyl)-3-methoxy-3,4-dihydro-2h-chromene-5,7-diol Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2OC)=CC=C(O)C(O)=C1 PDHSAQOQVUXZGQ-JKSUJKDBSA-N 0.000 claims description 2
- AALXZHPCKJILAZ-UHFFFAOYSA-N (4-propan-2-ylphenyl)methyl 2-hydroxybenzoate Chemical compound C1=CC(C(C)C)=CC=C1COC(=O)C1=CC=CC=C1O AALXZHPCKJILAZ-UHFFFAOYSA-N 0.000 claims description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- OIQXFRANQVWXJF-UHFFFAOYSA-N 2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical class CC1(C)C2CCC1(C)C(=O)C2=CC1=CC=CC=C1 OIQXFRANQVWXJF-UHFFFAOYSA-N 0.000 claims description 2
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 claims description 2
- VSXIZXFGQGKZQG-UHFFFAOYSA-N 2-cyano-3,3-diphenylprop-2-enoic acid Chemical compound C=1C=CC=CC=1C(=C(C#N)C(=O)O)C1=CC=CC=C1 VSXIZXFGQGKZQG-UHFFFAOYSA-N 0.000 claims description 2
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 claims description 2
- LUKNZSDCSDDKNC-UHFFFAOYSA-N 3-benzylidene-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one methyl hydrogen sulfate Chemical compound COS(O)(=O)=O.CC1(C)C2CCC1(C)C(=O)C2=CC1=CC=CC=C1 LUKNZSDCSDDKNC-UHFFFAOYSA-N 0.000 claims description 2
- RJCHCFQTUKAYAA-UHFFFAOYSA-N 5-[[2-amino-5-[(4-methoxyphenyl)methyl]-3-methylimidazol-4-yl]methyl]-2-methoxybenzene-1,3-diol Chemical compound C1=CC(OC)=CC=C1CC1=C(CC=2C=C(O)C(OC)=C(O)C=2)N(C)C(=N)N1 RJCHCFQTUKAYAA-UHFFFAOYSA-N 0.000 claims description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 2
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 claims description 2
- 229940064734 aminobenzoate Drugs 0.000 claims description 2
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 2
- 150000005417 aminobenzoic acid derivatives Chemical class 0.000 claims description 2
- 229960005193 avobenzone Drugs 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 claims description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 2
- 229930016911 cinnamic acid Natural products 0.000 claims description 2
- 235000013985 cinnamic acid Nutrition 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001173 oxybenzone Drugs 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 claims description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 2
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000368 sulisobenzone Drugs 0.000 claims description 2
- ZQTYRTSKQFQYPQ-UHFFFAOYSA-N trisiloxane Chemical compound [SiH3]O[SiH2]O[SiH3] ZQTYRTSKQFQYPQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 3
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims 1
- 239000012965 benzophenone Substances 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 35
- 239000000499 gel Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000010410 layer Substances 0.000 description 10
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 8
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 8
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 description 8
- 229960002568 ethinylestradiol Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229960004101 bemotrizinol Drugs 0.000 description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 6
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000004224 protection Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 5
- 229960000991 ketoprofen Drugs 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- NHZIBLPDGIARQC-UHFFFAOYSA-N sodium;4-hydroxy-5-(2-hydroxy-4-methoxybenzoyl)-2-methoxybenzenesulfonic acid Chemical compound [Na+].OC1=CC(OC)=CC=C1C(=O)C1=CC(S(O)(=O)=O)=C(OC)C=C1O NHZIBLPDGIARQC-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000002657 hormone replacement therapy Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 231100000760 phototoxic Toxicity 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZXSWTMLNIIZPET-ZOFHRBRSSA-N Normethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 ZXSWTMLNIIZPET-ZOFHRBRSSA-N 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960000270 methylestrenolone Drugs 0.000 description 2
- 229960004719 nandrolone Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- ATVKWBAMWLLBPS-UHFFFAOYSA-N 1h-benzimidazole-4,6-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2N=CNC2=C1 ATVKWBAMWLLBPS-UHFFFAOYSA-N 0.000 description 1
- AKUPYGILGNUOIG-UHFFFAOYSA-N 5-methoxy-4-phenyltriazine Chemical compound COC1=CN=NN=C1C1=CC=CC=C1 AKUPYGILGNUOIG-UHFFFAOYSA-N 0.000 description 1
- 208000012260 Accidental injury Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- HEAHZSUCFKFERC-IWGRKNQJSA-N [(2e)-2-[[4-[(e)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical group CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C\C(C=C1)=CC=C1\C=C/1C(=O)C2(CS(O)(=O)=O)CCC\1C2(C)C HEAHZSUCFKFERC-IWGRKNQJSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960004044 gestodene and ethinylestradiol Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- BLOZCRMCXQQOLK-UHFFFAOYSA-N n-(5,6-dioctyltriazin-4-yl)butanamide Chemical compound CCCCCCCCC1=NN=NC(NC(=O)CCC)=C1CCCCCCCC BLOZCRMCXQQOLK-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03028353A EP1541136A1 (de) | 2003-12-10 | 2003-12-10 | UV-Licht stabile halbfeste transdermale Systeme, die einen lichtempfindlichen Wirkstoff und einen UV-Absorber enthalten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200605632B true ZA200605632B (en) | 2008-06-25 |
Family
ID=34486168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200605632A ZA200605632B (en) | 2003-12-10 | 2006-07-07 | UV-light stable semi-solid transdermal systems that contain a light-sensitive substance and a UV-absorber |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP1541136A1 (zh) |
| JP (1) | JP2007534643A (zh) |
| KR (1) | KR20060096512A (zh) |
| CN (1) | CN101415402A (zh) |
| AR (1) | AR047140A1 (zh) |
| AU (1) | AU2004296539B2 (zh) |
| BR (1) | BRPI0416979A (zh) |
| CA (1) | CA2548739C (zh) |
| CR (1) | CR8461A (zh) |
| EA (1) | EA010239B1 (zh) |
| EC (1) | ECSP066689A (zh) |
| GT (1) | GT200400261A (zh) |
| HN (1) | HN2004000525A (zh) |
| IL (1) | IL176208A0 (zh) |
| MX (1) | MXPA06006534A (zh) |
| MY (1) | MY141728A (zh) |
| NO (1) | NO20063208L (zh) |
| NZ (1) | NZ547733A (zh) |
| PE (1) | PE20050863A1 (zh) |
| SV (1) | SV2006001971A (zh) |
| TW (1) | TW200528136A (zh) |
| UA (1) | UA85861C2 (zh) |
| WO (1) | WO2005055975A2 (zh) |
| ZA (1) | ZA200605632B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI395806B (zh) | 2010-04-14 | 2013-05-11 | Ind Tech Res Inst | 封裝材料 |
| WO2012031999A2 (en) | 2010-09-06 | 2012-03-15 | Bayer Pharma Aktiengesellschaft | Low-dose transdermal patches with high drug release |
| US10293023B2 (en) | 2013-03-15 | 2019-05-21 | Children's Medical Center Corporation | Method of altering vascular permeability and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60155111A (ja) * | 1983-10-20 | 1985-08-15 | Hisamitsu Pharmaceut Co Inc | 安定なケトプロフェン含有外用経皮製剤 |
| JP2981523B2 (ja) * | 1990-11-19 | 1999-11-22 | 株式会社林原生物化学研究所 | 皮膚外用剤 |
| AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| CN1276714A (zh) * | 1997-08-21 | 2000-12-13 | 强生消费品公司 | 17－α－雌二醇在处理衰老或日光损伤皮肤和/或皮肤萎缩上的应用 |
| JP2000292428A (ja) * | 1999-04-05 | 2000-10-20 | Umeda Jimusho:Kk | 環境化学物質の内分泌攪乱活性の新規測定方法及びその装置 |
| JP2001129566A (ja) * | 1999-11-05 | 2001-05-15 | Mitsubishi Heavy Ind Ltd | 有害物質処理方法およびその装置 |
| FR2804024B1 (fr) * | 2000-01-21 | 2002-09-13 | Menarini France | Nouvelles compositions pharmaceutiques a action anti- inflammatoire et leur procede de preparation |
| DE10053375C1 (de) * | 2000-10-27 | 2002-01-24 | Lohmann Therapie Syst Lts | Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen |
| FR2834895B1 (fr) * | 2002-01-22 | 2006-06-23 | Ellipse Pharmaceuticals | Compositions dermatologiques, resistantes a l'eau, avec filtres solaires, procede de fabrication et utilisations de ces compositions |
| ITFI20020144A1 (it) * | 2002-08-01 | 2004-02-02 | Menarini Farma Ind | Formulazioni topiche stabilizzate contenenti ketoprofene. |
-
2003
- 2003-12-10 EP EP03028353A patent/EP1541136A1/de not_active Withdrawn
-
2004
- 2004-06-12 UA UAA200607539A patent/UA85861C2/uk unknown
- 2004-12-02 TW TW93137245A patent/TW200528136A/zh unknown
- 2004-12-06 EP EP04803546A patent/EP1703892A2/de not_active Withdrawn
- 2004-12-06 WO PCT/EP2004/013839 patent/WO2005055975A2/de active Application Filing
- 2004-12-06 CA CA002548739A patent/CA2548739C/en not_active Expired - Fee Related
- 2004-12-06 NZ NZ547733A patent/NZ547733A/en unknown
- 2004-12-06 BR BRPI0416979-4A patent/BRPI0416979A/pt not_active IP Right Cessation
- 2004-12-06 AU AU2004296539A patent/AU2004296539B2/en not_active Ceased
- 2004-12-06 KR KR1020067013775A patent/KR20060096512A/ko not_active Application Discontinuation
- 2004-12-06 JP JP2006543451A patent/JP2007534643A/ja active Pending
- 2004-12-06 CN CNA2004800369947A patent/CN101415402A/zh active Pending
- 2004-12-06 EA EA200601084A patent/EA010239B1/ru not_active IP Right Cessation
- 2004-12-10 PE PE2004001228A patent/PE20050863A1/es not_active Application Discontinuation
- 2004-12-10 GT GT200400261A patent/GT200400261A/es unknown
- 2004-12-10 AR ARP040104604A patent/AR047140A1/es unknown
- 2004-12-10 HN HN2004000525A patent/HN2004000525A/es unknown
- 2004-12-10 MY MYPI20045109A patent/MY141728A/en unknown
- 2004-12-10 SV SV2004001971A patent/SV2006001971A/es not_active Application Discontinuation
-
2006
- 2006-06-08 MX MXPA06006534 patent/MXPA06006534A/es unknown
- 2006-06-08 IL IL176208A patent/IL176208A0/en unknown
- 2006-06-16 CR CR8461A patent/CR8461A/es not_active Application Discontinuation
- 2006-07-07 ZA ZA200605632A patent/ZA200605632B/en unknown
- 2006-07-07 EC EC2006006689A patent/ECSP066689A/es unknown
- 2006-07-10 NO NO20063208A patent/NO20063208L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007534643A (ja) | 2007-11-29 |
| AU2004296539B2 (en) | 2008-10-09 |
| CA2548739C (en) | 2009-08-18 |
| EA200601084A1 (ru) | 2006-12-29 |
| ECSP066689A (es) | 2006-10-31 |
| BRPI0416979A (pt) | 2007-02-21 |
| CN101415402A (zh) | 2009-04-22 |
| CR8461A (es) | 2006-12-07 |
| TW200528136A (en) | 2005-09-01 |
| SV2006001971A (es) | 2006-02-15 |
| MY141728A (en) | 2010-06-15 |
| WO2005055975A3 (de) | 2009-03-12 |
| EA010239B1 (ru) | 2008-06-30 |
| NO20063208L (no) | 2006-07-10 |
| HN2004000525A (es) | 2010-09-17 |
| WO2005055975A2 (de) | 2005-06-23 |
| AU2004296539A1 (en) | 2005-06-23 |
| AR047140A1 (es) | 2006-01-11 |
| EP1703892A2 (de) | 2006-09-27 |
| PE20050863A1 (es) | 2005-11-02 |
| NZ547733A (en) | 2010-02-26 |
| UA85861C2 (uk) | 2009-03-10 |
| IL176208A0 (en) | 2006-10-05 |
| KR20060096512A (ko) | 2006-09-11 |
| GT200400261A (es) | 2005-10-31 |
| CA2548739A1 (en) | 2005-06-23 |
| MXPA06006534A (es) | 2006-08-01 |
| EP1541136A1 (de) | 2005-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050129756A1 (en) | UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient | |
| AU676562B2 (en) | Solubilizing agent and external preparation containing the same | |
| EP0782861B1 (en) | Drug compounding ingredients comprising n-substituted-o-toluidine derivative and percutaneously absorbable preparation | |
| US20150150827A1 (en) | Multi-layered transdermal system with triazine uv absorber | |
| ES2399900T3 (es) | Composición farmacéutica que comprende un andrógeno | |
| HU221598B (hu) | Glicerin alkalmazása bőrön keresztüli hatóanyag-bevitel szabályozására | |
| JP5075622B2 (ja) | 非ステロイド系消炎鎮痛剤を含有する外用経皮製剤 | |
| IL176112A (en) | Skin-containing preparation through the stomach containing gastodone and carrier, a medical system for the administration through the skin containing gastodon and a kit | |
| EP1752164B1 (en) | Percutaneous pharmaceutical preparation for external use containing nonsteroidal antiinflammatory analgesic | |
| ZA200605632B (en) | UV-light stable semi-solid transdermal systems that contain a light-sensitive substance and a UV-absorber | |
| EP2138169B1 (en) | Transdermal delivery system of hormones without penetration enhancers | |
| SK126093A3 (en) | Lanoline derivatives as a penetration-promoting substances | |
| US20180078493A1 (en) | Transdermal hormone delivery | |
| KR20080003854A (ko) | Ｕｖ 흡수제를 포함하는 고상 경피 치료 시스템 | |
| EA007351B1 (ru) | Фармацевтическая композиция для чрескожной доставки физиологически активных агентов | |
| JP2852816B2 (ja) | 溶解剤および該溶解剤を含有する外用製剤 | |
| KR20070015954A (ko) | 비스테로이드계 소염 진통제를 함유하는 외용 경피 제제 |